Revvity, Inc.

Laboratory Analytical Instruments

RVTYStrained8 of 11 basics passed

$154.18

+1.33%

Market cap $17.2B

$154.18

+1.33%

Market cap $17.2B

Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer.

It is a $17.2B technology company. Revenue grew 4.1% over the last year, it keeps 8¢ of every dollar of sales as profit, and its net debt equals ~3.1 years of free cash flow. It trades at 72.4× earnings — near the highest of its own history.

Website: revvity.com
Location: Waltham, MA
Employees: 11 000
Sector: Technology

Share price · 3 years

$110.07 → $154.18+40.1%

price only — dividends excluded

Key facts · TTM

Revenue: total sales; $2.91B
Profit: keeps 8¢ of every $1 sold; $238M
Free cash flow: cash left after running the business; $558M
Net debt: debt minus cash on hand; $1.71B
P/E: years of profit in the price; 72.4
EPS: earnings per share, TTM; $1.97
Dividend: pays out 13% of profit · 6% of FCF; 0.18%
Shares: up 3% since 2021 — dilution; 120.6M
Volatility: beta vs the market — under 1 swings less; 1.09

Revenue, last 5 years

52-week range

Low $82.26$154.18High $157.36

Today's price is 96% of the way from the year's low to its high.

P/E vs its history3y

72.4×median 43.4×

Higher than 92% of past days — near the highest of its own history.

Valuation vs own history

P/E

72.4×

P/S

5.9×

17%

EV/EBITDA

48.1×

52%

P/B

2.4×

FCF yield

3.2%

27%

Share of the last ~5 years that was pricier than today (pricier than usual). Based on the daily valuation record.

Insider activity · 90 days

-$1.29Mnet selling

Purchases$0

Sales$1.29M

Insiders trading, last 14d0 buy · 1 sell

Standing in Technology

Size$17.2Btop 64%
Revenue growth-5%top 94%
Net margin8%top 66%
Return on equity3%top 80%
P/E72.4×top 79%
Dividend yield0.18%top 87%

Ranked against 220 Technology companies with a full CV — for P/E, lower ranks higher.

Skills

Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.

Strong quality; Valuation, Growth, Profitability and Health lag behind.

Valuation29

P/E vs own history92th pct · 0/25
FCF yield3.2% · 12/25
P/S5.9x · 12/25
EV/EBITDA25.1x · 5/25

Growth25

Revenue CAGR-7.1% · 0/25
Net income CAGR-28.9% · 0/25
EPS CAGR ~5Y-29.5% · 0/25
Fwd implied growth189.9% · 25/25

Profitability35

ROIC2.7% · 5/25
ROE3.3% · 5/25
Net margin8.2% · 13/25
Operating margin12.3% · 12/25

Health40

Altman Zn/a · 0/25
Current ratio1.80 · 18/25
Interest coverage4.1x · 10/25
Net cash / debtD/A 14% · 12/25

Quality77

Piotroski F6/9 · 15/25
Beneish M-2.59 · 25/25
FCF conversion235% · 25/25
Margin stabilityσ 9.1% · 12/25

Moat68

ROIC >12% years0/5 yrs · 0/25
Median gross margin56.0% · 25/25
FCF-positive years5/5 yrs · 25/25
Worst-year net marginworst 8.4% · 18/25

How the scores work →

Experience

The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.

2026Product
Revvity Signals Software business announced it joined Anthropic's directory for Model Context Protocol…
2025Product
Revvity’s Euroimmun launched the IDS i20 analytical random access platform, enabling full automation of…
2023Acquisition
Revvity's Euroimmun business received CE-IVDR certification for the UNIQO 160, an automated indirect…
FY2021Financial
Profitable every year on record
5 consecutive profitable years in our data
FY2021Financial
Revenue already above $1B
$3.83B in first reported year
FY2021Financial
Positive free cash flow every year since
5-year streak
FY2021Financial
Best year on record
$943M net income

Achievements

Verifiable track record, straight from the reported numbers.

$10 000 invested in 2023 would be worth ~$13 500 today — price return only

$2.9B revenue in FY2025

Profitable 5 years in a row

Positive free cash flow 5 years in a row

11 000 employees

Strengths & watch-outs

What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.

Strengths

High gross margin (55.0%)
Strong cash conversion — FCF is 19.2% of revenue

Watch-outs

Nothing stands out as a concern in the available data.

Qualifications

The basics a company should meet before you research it further. Each check uses the reported numbers.

8 of 11 checks passed

Revenue growing — the company sells more than a year ago+4.1% YoY
Profitable — makes more than it spends$238M TTM
Profit growing — earnings are higher than last year-22.8% YoY
Generates cash — cash left after running and investing$558M TTM
Debt under control — could handle its obligations~3.1y of cash flow to repay
Established company — not a micro-cap — lower blow-up risk$17.2B market cap
Not printing shares — share count not ballooning — you keep your slice+3.3% shares over ~5y
Proven track record — years of profitability behind it5/5 profitable years
Financially stable — balance sheet not near distresshealth score 28/100
Pays a dividend — returns cash to shareholdersyield 0.18%
Valuation not extreme — price not wildly above earningsP/E 72.4

Peer comparisonRevvity, Inc. vs 6 largest technology peers — cap, P/E, growth and margin side by sideOpen ▾

Company	Market cap	P/E	Revenue growth	Net margin	Profile
RVTY this company	$17.2B	72.4	+4.1%	8.2%	Strained
NVDA Nvidia Corp	$5.5T	28.6	+83.4%	63.7%	Mixed
AAPL Apple Inc.	$4.9T	38.1	+14.2%	27.6%	Strong
GOOGL Alphabet Inc.	$4.3T	17.6	+20.1%	54.8%	Mixed
MSFT Microsoft Corp	$4.0T	29.7	+17.8%	40.3%	Strong
SPCX Space Exploration Technologies Corp.	$2.1T	—	+33.2%	-34.0%	Strained
META Meta Platforms, Inc.	$1.8T	26.9	+27.7%	29.8%	Mixed

Head-to-head: RVTY vs NVDA · RVTY vs AAPL · RVTY vs GOOGL

References

What covering analysts publish about the company — information only, not a recommendation.

Strong buy 5Buy 8Hold 12

Appendix · Financial records

The full statements behind this CV, FY2021–FY2025. For readers who want to check the numbers.

Profit & lossRevenue $2.91B · net income $238M (TTM)Open ▾

Profit & loss

Revenue and profit over the company's career — the income statement, visualised.

How FY2025 revenue flows to profit

RevenueNet income

Revenue (TTM)

$2.91B

YoY 4.1%

Net income (TTM)

$238M

Margin 8.2%

Gross margin

55.0%

Operating margin

12.3%

P/E ratio

72.4

Dividend yield

0.18%

Income statement — full detail

Figures in USD billions · EPS in USD

	2021	2022	2023	2024	2025
Revenue	3.8	3.3	2.8	2.8	2.9
Gross profit	2.5	2.0	1.5	1.5	1.6
Operating income (EBIT)	1.4	0.8	0.3	0.3	0.4
Net income	0.9	0.6	0.7	0.3	0.2
EPS (diluted)	8.08	4.51	5.00	2.00	2.00

Cash flowFree cash flow $558M · operating cash flow $628M (TTM)Open ▾

Cash flow statement

Cash generated by the business and what is left after investment — year by year.

Operating cash flowFree cash flow

Free cash flow (TTM)

$558M

Margin 19.2%

Operating cash flow (TTM)

$628M

FCF margin

19.2%

Cash flow statement — full detail

Figures in USD billions

	2021	2022	2023	2024	2025
Operating cash flow	1.4	0.7	0.1	0.6	0.6
Capital expenditure	-0.1	-0.1	-0.1	-0.1	-0.1
Free cash flow	1.3	0.6	0.0	0.5	0.5
FCF margin	34.6%	17.9%	0.4%	19.7%	17.8%

Balance sheetAssets $12.2B · net debt $1.71B (FY2025)Open ▾

Balance sheet

How the balance sheet is built — what it owns versus how it is financed.

How $12.2B of assets is financed

40%

60%

Liabilities $4.92B — borrowed moneyEquity $7.25B — owners' stake

Cash vs debt

Total debt $2.63B − cash $920M = net debt $1.71B

Cash on hand covers 35% of debt.

Debt repayment

0.0 yrs

Years of free cash flow to clear net debt

Interest coverage

4.1x

EBIT ÷ interest expense

ROE

3.3%

Profit per $1 of equity

Balance sheet — full detail

Figures in USD billions

	2021	2022	2023	2024	2025
Cash & equivalents	0.6	0.5	1.6	1.2	0.9
Total assets	15.0	14.1	13.6	12.4	12.2
Total liabilities	7.9	6.7	5.7	4.7	4.9
Total debt	5.2	4.6	3.2	3.2	2.6
Equity	7.1	7.4	7.9	7.7	7.3
Net debt	4.6	4.1	1.6	2.0	1.7

Want the live picture — intraday moves, valuation history and full analysis?

Deeper analysis of RVTY on PreMarketPrice

Figures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $154.18 · market cap $17.2B.